RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.
